

## [Metronidazole](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.1. Antiamoebic and anti-giardiasis medicines](#)

ATC codes: [P01AB01](#)

EMLc

Indication

Amoebiasis ICD11 code: [1A36.Z](#)

INN

Metronidazole

Medicine type

Chemical agent

Antibiotic groups

[ACCESS](#)

List type

Core

Formulations

**Oral > Liquid:** 200 mg per 5 mL (as benzoate)

**Parenteral > General injections > unspecified:** 500 mg in 100 mL vial

**Oral > Solid > tablet:** 200 mg ; 250 mg ; 400 mg ; 500 mg

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1982 ([TRS 685](#))

Changed in 1987 ([TRS 770](#))

Changed in 2007 ([TRS 950](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

[tinidazole](#) (ATC codes: [P01AB02](#) [J01XD02](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Metronidazole](#)

DrugBank

[Metronidazole](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended that the range of strengths of metronidazole tablets be replaced with reference to specific strengths on the EML and EMLc.